Arcus Biosciences, Inc. (RCUS) Free cash flow 2016–2025
Arcus Biosciences, Inc. (RCUS) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$484.0MFY2025 · since FY2016: -$17.0M → -$484.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$484.0M | -175.0% |
| FY2024 | -$176.0M | +46.7% |
| FY2023 | -$330.0M | -176.4% |
| FY2022 | $432.0M | +253.2% |
| FY2021 | -$282.0M | -361.1% |
| FY2020 | $108.0M | +243.3% |
| FY2019 | -$75.4M | -61.3% |
| FY2018 | -$46.7M | -52.9% |
| FY2017 | -$30.6M | -79.4% |
| FY2016 | -$17.0M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More RCUS financial trends
RCUS RevenueRCUS Net incomeRCUS Net marginRCUS Gross profitRCUS Gross marginRCUS Operating incomeRCUS Operating marginRCUS Operating cash flowRCUS Capital expendituresRCUS Return on equityRCUS Stock buybacksRCUS Dividends paidRCUS Total assetsRCUS Total liabilitiesRCUS Shareholders’ equityRCUS overview →